Prescient Therapeutics Ltd has released a press release.
December 2025 Quarterly Update and Appendix 4C
Earlier from Prescient Therapeutics
- PTX secures EU Authorisation to commence PTX-100 Trial
- PTX secures EU Orphan Drug Designation for PTX-100 in CTCL
- September Quarterly Updated and Appendix 4C
- Appendix 4E and 2025 Annual Report